Peptide Show podcast

Dr Edwin Lee: Do you know peptides better than your doctor?

11/17/2026
0:00
28:09
Rewind 15 seconds
Fast Forward 15 seconds

Ten peptide vials in a Ziploc bag. No labels. 

One of Dr Edwin Lee’s sons took the photo at college. The vials belonged to his roommate, who was into peptides. There was no way to tell what was in them. At a swimming pool, a 22-year-old lifeguard told Edwin he was using peptides too. Edwin reckoned the lifeguard knew more about them than many doctors. 

Edwin is an endocrinologist and co-founder of the Clinical Peptide Society, where he teaches clinicians about peptides. 

He joins Richard Skaife to talk about what patients are already trying, what doctors are being asked to prescribe, and what happens when someone has a side effect and nobody records it. 

He explains

■ What a “yes” from FDA advisers means for peptides such as BPC-157 and Epitalon
■ Why he wants a registry that makes peptide side effects visible
■ Why he starts with sleep, nutrition, and hormones before introducing peptides in his own practice
■ What he’d want a larger human trial to answer about SS-31 and diabetic kidney disease
■ How he’d test BPC-157 and thymosin beta 4 for knee injuries to see whether either works alone, whether the combination works better, or whether placebo tells a different story

Chapters

  • (00:00) - Intro
  • (00:40) - Meet Dr Edwin Lee
  • (02:01) - How Edwin got into peptides
  • (04:25) - How the peptide gray market took off
  • (05:58) - What does a “yes” from FDA advisers mean?
  • (09:18) - Are doctors keeping up with peptides?
  • (14:22) - Who’s tracking peptide side effects?
  • (17:03) - Sleep, hormones, and Edwin’s approach
  • (20:55) - When patients ask for peptides by name
  • (22:07) - The human trials Edwin would run
  • (24:19) - Could peptides become a $100 billion market?

Watch the full episode on YouTube

Further reading

FDA. The July 2026 advisory meeting materials name the seven peptide groups under consideration and the uses the FDA reviewed for each. Read the FDA meeting materials

Dinetz and Lee. Edwin co-authored a narrative review of human studies on thymosin alpha 1, the peptide he discusses from an earlier FDA advisory meeting. Read the review on PubMed

FDA MedWatch. The FDA’s existing reporting program accepts reports from patients and health professionals about suspected serious reactions and product quality problems. See how MedWatch works

Read the full transcript

Follow Dr Edwin Lee

Clinical Peptide Society: Edwin Lee’s profile

Follow Richard Skaife

LinkedIn: linkedin.com/in/richardskaife/

Peptide Show

Website: Peptide.Show
Instagram: @Peptide.Show
TikTok: @peptide.show
Facebook: Peptide Show
X: @peptideshow
YouTube: @PeptideShow

Peptide Show explores the science, medicine, business, and people shaping the rapidly evolving world of peptides.

Presented by Longr: longr.io

Follow Peptide Show for new episodes every Tuesday.

This podcast is for informational and educational purposes only. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements.

More episodes from "Peptide Show"